On the other hand, BRAF fusions were identified in 0.2% of 17,128 NSCLC samples, with the most frequent partner genes being AGK, DOCK4, and TRIM24, and the most frequently co-occurring mutations being TP53 (67%), CDKN2A (31%), EGFR (29%), and CDKN2B (26%) [67]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.